Perfuse Therapeutics宣布将在视觉与眼科研究协会（ARVO）会议上进行关于PER-001玻璃体内植入物治疗青光眼的口头报告-动脉网

Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting

CISION 等信源发布 2025-04-21 22:00



可切换为仅中文







– Oral presentation to highlight 6-month data from all cohorts of the completed Phase 1/2a clinical trial –

– 口头报告重点介绍已完成的1/2a期临床试验中所有队列的6个月数据 –

SAN FRANCISCO

旧金山

，

April 21, 2025

2025年4月21日

/PRNewswire/ -- Perfuse Therapeutics, Inc. ('Perfuse Therapeutics'), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced that an oral presentation on PER-001 intravitreal implant for glaucoma has been accepted for the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025 being held .

/PRNewswire/ -- Perfuse Therapeutics, Inc.（“Perfuse Therapeutics”），一家致力于开发治疗缺血性眼病的变革性疗法的生物制药公司，今日宣布，关于PER-001玻璃体内植入物治疗青光眼的口头报告已被接受，将在2025年举行的视觉与眼科研究协会（ARVO）年会上展示。

May 4 to May 8, 2025

2025年5月4日至2025年5月8日

, in

，在

Salt Lake City, Utah

犹他州盐湖城

. PER-001 is a first-in-class endothelin antagonist for ocular diseases being developed for the treatment of glaucoma and other ocular indications driven by ischemia.

PER-001是一种首创新药的内皮素拮抗剂，用于治疗青光眼和其他由缺血引起的眼部疾病。

The oral presentation will share data from all three cohorts of patients with glaucoma in the completed Phase 1/2a clinical trial. The data expand beyond earlier findings from the Phase 1 and Phase 2a (low dose) cohorts presented at the

口头报告将分享已完成的1/2a期临床试验中所有三个青光眼患者队列的数据。这些数据扩展了之前在第1阶段和第2a阶段（低剂量）队列中展示的结果。

American Glaucoma Society Meeting

美国青光眼学会会议

在

March 2025

2025年3月

, demonstrating that PER-001 is well tolerated and shows promise as the first disease-modifying therapy for glaucoma.

，这表明 PER-001 具有良好的耐受性，并有望成为青光眼的首个疾病修饰疗法。

Oral Presentation Details

口头报告详情

Title:

标题：

PER-001, an endothelin antagonist, increased optic nerve head blood flow with structural and functional improvements in patients with glaucoma

PER-001，一种内皮素拮抗剂，增加了青光眼患者的视神经头血流量，并带来了结构和功能的改善。

Date & Time:

日期与时间：

Tuesday, May 6, 2025 at 2:45–3:00 p.m. MDT

2025年5月6日星期二下午2点45分至3点（山区夏令时间）

Abstract Number:

摘要编号：

3322

Session Title:

会议标题：

Glaucoma: Ocular blood flow and vascular pathophysiology

青光眼：眼部血流和血管病理生理学

Location:

位置：

Ballroom G

G大厅

Presenter:

主持人：

Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Glaucoma Services, Legacy Devers Eye Institute

史蒂文·曼斯伯格医学博士，公共卫生硕士，眼科主任兼青光眼服务主任，莱加西德弗斯眼科研究所

About PER-001 Intravitreal Implant, a Long-Acting Endothelin Receptor Antagonist

关于PER-001玻璃体内植入物，一种长效内皮素受体拮抗剂

PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells.

PER-001 是一种新型（新化学实体）、首创的小分子内皮素受体拮抗剂。内皮素是人体中最有效的血管收缩剂，在青光眼中表达上调。内皮素通过其在视网膜血管和神经视网膜细胞中表达的受体参与炎症和细胞死亡。

The PER-001 intravitreal implant is a bio-erodible implant, administered into the vitreous cavity of the eye using a single use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient every 6 months dosing frequency..

PER-001玻璃体内植入物是一种生物可降解植入物，使用一次性25号规格注射器注入眼球的玻璃体腔内，旨在提供PER-001的持续释放，从而实现每6个月一次的便捷给药频率。

About the Phase 1/2a Clinical Trial

关于第1/2a期临床试验

The Phase 1/2a is a multi-center, two-part clinical trial designed to assess the safety, tolerability and pharmacodynamics of PER-001 in patients with glaucoma. The Phase 1 part of the trial was a first-in-human, open-label, single ascending dose (SAD) study that evaluated the safety and tolerability of two doses (low dose, high dose) of PER-001 intravitreal implant in patients with advanced glaucoma.

第1/2a期是一项多中心、两部分的临床试验，旨在评估PER-001在青光眼患者中的安全性、耐受性和药效学。第1期试验是首次人体试验，开放标签、单剂量递增（SAD）研究，评估了两种剂量（低剂量和高剂量）的PER-001玻璃体内植入物在晚期青光眼患者中的安全性和耐受性。

The Phase 2a part of the trial was a patient- and reading-center masked, randomized, sham-controlled study that evaluated the safety, tolerability, and pharmacodynamics of the same two doses of PER-001 in patients with progressing, mild to moderate glaucoma..

该试验的第2a阶段部分是一项患者和阅读中心设盲、随机、假对照研究，评估了PER-001相同两种剂量在进展性轻至中度青光眼患者中的安全性、耐受性和药效学。

All patients received a single intravitreal administration of PER-001 while maintaining their pre-study intraocular pressure (IOP)-lowering therapies. In the Phase 1 SAD part of the trial, two doses of PER-001 intravitreal implant were tested in patients (n=6). In the Phase 2a part of the trial, the same two doses, along with a sham, were subsequently tested in patients (n=27).

所有患者在接受 PER-001 单次玻璃体内注射的同时，继续维持他们在研究前的眼内压 (IOP) 降低治疗。在试验的 1 期 SAD 部分，对患者 (n=6) 测试了两种剂量的 PER-001 玻璃体内植入物。在 2a 期试验部分，同样的两种剂量以及安慰剂随后在患者 (n=27) 中进行了测试。

All patients were followed for 24 weeks after receiving a single dose..

所有患者在接受单剂量给药后均随访了24周。

About Perfuse Therapeutics, Inc.

关于Perfuse治疗公司

Perfuse Therapeutics is a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases. Enabled by its proprietary sustained release drug delivery platform, the Company is developing a robust pipeline of novel assets against validated targets. Headquartered in .

Perfuse Therapeutics是一家生物制药公司，致力于开发治疗缺血性眼病的变革性疗法。公司依托其专有的缓释药物递送平台，正在开发针对已验证靶点的多样化新型资产组合。总部位于。

South San Francisco, California

加利福尼亚州南旧金山

and with R&D facilities in

并在以下地方设有研发设施

Durham, North Carolina

北卡罗来纳州达勒姆

, Perfuse Therapeutics has established a strong team committed to advancing disease modifying therapies to patients with ocular disease around the world. For more information, please see

，Perfuse Therapeutics组建了一支强大的团队，致力于为全球眼疾患者推进疾病修饰治疗。欲了解更多信息，请参见

www.perfusetherapeutics.com

and on LinkedIn.

并在领英上。

Contact Information:

联系信息：

Lori Rosen

洛丽·罗森

Red House Communications

红房子通讯

lori@redhousecomms.com

SOURCE Perfuse Therapeutics